Slide 1: Title Slide • Slide Title: Lifelong Protection: The 2026 Blueprint for Adult Immunisation in Malaysia • Subtitle: Implementing the 4th Edition MSIDC Guidelines & National Policy Updates • Visual Suggestion: A clean medical theme with the corporate colors of Malaysia's healthcare sector (Teal/Blue) and a subtle graphic representing life-course immunity. • Presenter Notes: Welcome everyone. Today we are looking at the critical pivot Malaysia is making from a childhood-centric model to a comprehensive, life-course adult immunization strategy, updated with the latest July 2026 clinic standards. Slide 2: Why Adult Immunisation Matters in 2026 • Slide Title: The Shift to Life-Course Immunisation • Bullet Points: • Waning Immunity: Childhood vaccine efficacy declines significantly over decades. • Ageing Nation Status: Malaysia's shifting demographics increase vulnerability to infectious diseases. • Comorbidity Risks: High national prevalence of diabetes, hypertension, and obesity drastically increases vaccine-preventable disease (VPD) severity. • Economic Impact: Mitigating avoidable adult hospitalizations protects workforce productivity and healthcare infrastructure. • Visual Suggestion: A dual-axis layout contrasting standard childhood schedules against the new comprehensive adult age categories. Slide 3: Major 2026 Policy Milestones (MOH Malaysia) • Slide Title: National Influenza Immunisation Expansion • Bullet Points: • Free Flu Vaccines: Fully funded routine influenza shots now expanded via the government. • Universal Senior Tier: Available to ALL Malaysian citizens aged 60 and above, regardless of underlying health conditions. • High-Risk Adult Tier: Available to citizens aged 50 to 59 living with at least one chronic comorbidity (e.g., diabetes, heart disease, chronic kidney disease). • Digital Integration: Bookings, tracking, and allocations integrated into the national MySejahtera platform. • Visual Suggestion: An illustrative timeline showing the transition from previous narrow criteria to the massive 2026 universal rollouts. Slide 4: Core Schedule – Young Adults to Middle Age (18–49 Years) • Slide Title: Immunisation Priorities: Ages 18 to 49 • Bullet Points: • Tdap Booster: 1 dose of Tdap (Tetanus, Diphtheria, Pertussis) followed by a Td booster strictly every 10 years. • HPV Vaccine: 2–3 doses recommended up until age 45 if not completed during school years. • MMR & Varicella: 1–2 doses for individuals lacking documented historical childhood evidence or laboratory titers. • Hepatitis B: 3-dose catch-up series recommended for unvaccinated adults. • Visual Suggestion: Icons highlighting workplace and familial immunity, focusing on protecting vulnerable infants at home. Slide 5: Core Schedule – Older Adults & Seniors (Ages 50 to 65+) • Slide Title: Immunisation Priorities: Ages 50 to 65+ • Bullet Points: • Annual Influenza: 1 dose yearly for all seniors to combat immunosenescence. • Pneumococcal (PCV20): 1 standalone do
Slide 1: Title Slide • Slide Title: Lifelong Protection: The 2026 Blueprint for Adult Immunisation in Malaysia • Subtitle: Implementing the 4th Edition MSIDC Guidelines & National Policy Updates • Visual Suggestion: A clean medical theme with the corporate colors of Malaysia's healthcare sector (Teal/Blue) and a subtle graphic representing life-course immunity. • Presenter Notes: Welcome everyone. Today we are looking at the critical pivot Malaysia is making from a childhood-centric model to a comprehensive, life-course adult immunization strategy, updated with the latest July 2026 clinic standards. Slide 2: Why Adult Immunisation Matters in 2026 • Slide Title: The Shift to Life-Course Immunisation • Bullet Points: • Waning Immunity: Childhood vaccine efficacy declines significantly over decades. • Ageing Nation Status: Malaysia's shifting demographics increase vulnerability to infectious diseases. • Comorbidity Risks: High national prevalence of diabetes, hypertension, and obesity drastically increases vaccine-preventable disease (VPD) severity. • Economic Impact: Mitigating avoidable adult hospitalizations protects workforce productivity and healthcare infrastructure. • Visual Suggestion: A dual-axis layout contrasting standard childhood schedules against the new comprehensive adult age categories. Slide 3: Major 2026 Policy Milestones (MOH Malaysia) • Slide Title: National Influenza Immunisation Expansion • Bullet Points: • Free Flu Vaccines: Fully funded routine influenza shots now expanded via the government. • Universal Senior Tier: Available to ALL Malaysian citizens aged 60 and above, regardless of underlying health conditions. • High-Risk Adult Tier: Available to citizens aged 50 to 59 living with at least one chronic comorbidity (e.g., diabetes, heart disease, chronic kidney disease). • Digital Integration: Bookings, tracking, and allocations integrated into the national MySejahtera platform. • Visual Suggestion: An illustrative timeline showing the transition from previous narrow criteria to the massive 2026 universal rollouts. Slide 4: Core Schedule – Young Adults to Middle Age (18–49 Years) • Slide Title: Immunisation Priorities: Ages 18 to 49 • Bullet Points: • Tdap Booster: 1 dose of Tdap (Tetanus, Diphtheria, Pertussis) followed by a Td booster strictly every 10 years. • HPV Vaccine: 2–3 doses recommended up until age 45 if not completed during school years. • MMR & Varicella: 1–2 doses for individuals lacking documented historical childhood evidence or laboratory titers. • Hepatitis B: 3-dose catch-up series recommended for unvaccinated adults. • Visual Suggestion: Icons highlighting workplace and familial immunity, focusing on protecting vulnerable infants at home. Slide 5: Core Schedule – Older Adults & Seniors (Ages 50 to 65+) • Slide Title: Immunisation Priorities: Ages 50 to 65+ • Bullet Points: • Annual Influenza: 1 dose yearly for all seniors to combat immunosenescence. • Pneumococcal (PCV20): 1 standalone do
Created using ChatSlide
This document outlines the necessity for a life-course immunisation strategy in Malaysia, emphasising the 2026 blueprint and the impact of waning immunity alongside ageing and comorbidities. It proposes the implementation of an Adult Immunisation Schedule prioritising adults aged 18-49, with a focus on influenza for those over 50 and high-risk groups. Finally, it advocates for translating policy into clinical practice by integrating eligibility and tracking systems in MySejahtera, adhering to...